T1	Participants 93 146	acute coronary syndrome in the PROVE IT-TIMI 22 trial
T2	Participants 441 505	a large cohort of patients presenting across the spectrum of ACS
T3	Participants 1006 1042	patients with elevated baseline PlGF
